Download PDF
Thromb Haemost 1995; 74(02): 797-798
DOI: 10.1055/s-0038-1649818
Letter to the Editor
Schattauer GmbH Stuttgart

Acquired Activated Protein C-Resistance in Patients with Lupus Anticoagulants

S Ehrenforth
Department of Internal Medicine, University Hospital, Frankfurt am Main, Germany
,
K P Radtke
Department of Internal Medicine, University Hospital, Frankfurt am Main, Germany
,
I Scharrer
Department of Internal Medicine, University Hospital, Frankfurt am Main, Germany
› Author Affiliations
Further Information

Publication History

Received 06 March 1995

Accepted after revision 05 April 1995

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci 1993; 90: 1004-1008
    CrossrefPubMedGoogle Scholar
  • 2 Greengard JS, Xi Su n, Xiao Xu, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-1362
    PubMedGoogle Scholar
  • 3 Bertina RM, Koeleman PB C, Koster T, Rosendaal RF, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
    CrossrefPubMedGoogle Scholar
  • 4 Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
    CrossrefPubMedGoogle Scholar
  • 5 Hampton KK, Path MR C, Preston FE, Greaves M. Resistance to activated protein C. N Engl J Med 1994; 331: 130
    CrossrefPubMedGoogle Scholar
  • 6 Bokarewa MI, Blombäck M, Egberg N, Rosen S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coag Fibrinolysis 1994; 5: 37-41
    CrossrefPubMedGoogle Scholar
  • 7 Thiagarajan P, Pengo V, Shapiro SS. The use of the diluted Russel viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874
    PubMedGoogle Scholar
  • 8 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural pattern. Br J Haematol 1978; 40: 143-151
    CrossrefPubMedGoogle Scholar
  • 9 Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79 (06) 678-682
    CrossrefPubMedGoogle Scholar
  • 10 Triplett DA, Stocker KF, Unger GA, Bama LK. The Textarin/Ecarin Ratio: A confirmatory Test for Lupus anticoagulants. Thromb Haemost 1993; 70 (06) 925-931
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Exner T, Triplett DA, Taberner D, Machin S. Guidelines for testing and revised criteria for Lupus Anticoagulants SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 1991; 65 (03) 320-322
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Halbmayer WM, Haushofer A, Schön R, Fischer M. Influence of lupus anticoagulant on a commercially available kit for APC resistance. Thromb Haemost 1994; 72 (04) 645-646
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Schwarz HP, Varadi K, Moritz B, Lang H, Bauer K, Preston E, Peake I, Rivard GE. A chromogenic assay for activated protein C (APC) resistance. Blood 1994; 84 Suppl (Suppl. 01) 84 a
    PubMedGoogle Scholar
  • 14 Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 1987; 57 (02) 144-147
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Marciniak E, Romond E. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-2432
    PubMedGoogle Scholar